Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma
Authors
Keywords
Melanoma, Imatinib, Focal Adhesion Kinase, Dasatinib, Melanoma Cell Line
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 21, Issue 3, Pages 1024-1030
Publisher
Springer Nature
Online
2013-11-26
DOI
10.1245/s10434-013-3387-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
- (2012) R. S. Turley et al. CLINICAL CANCER RESEARCH
- Molecular testing in malignant melanoma
- (2012) Allie H. Grossmann et al. DIAGNOSTIC CYTOPATHOLOGY
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
- (2011) A P Algazi et al. BRITISH JOURNAL OF CANCER
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- In vitro studies of dasatinib, its targets and predictors of sensitivity
- (2011) Lucia B. Jilaveanu et al. Pigment Cell & Melanoma Research
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma
- (2010) Hiroaki Toshimitsu et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
- (2010) Scott E. Woodman et al. BIOCHEMICAL PHARMACOLOGY
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
- (2010) C. K. Augustine et al. MOLECULAR CANCER THERAPEUTICS
- Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma
- (2010) Christina K. Augustine et al. MOLECULAR CANCER THERAPEUTICS
- Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
- (2009) Jade Homsi et al. MELANOMA RESEARCH
- Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
- (2009) S. E. Woodman et al. MOLECULAR CANCER THERAPEUTICS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion
- (2008) Georgia M. Beasley et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- (2008) K B Kim et al. BRITISH JOURNAL OF CANCER
- Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment
- (2008) C. K. Augustine et al. CANCER RESEARCH
- Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
- (2008) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
- (2008) Alex J Eustace et al. Journal of Translational Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now